For the current week, the overall ratings of four insurance stocks are worse, according to the Portfolio Graderdatabase. Each of these rates a “D” (“sell”) or “F” overall (“strong sell”).
XL Group Plc’s () rating falls to a D (“sell”) this week, down from C (“hold”) the week prior. XL provides property, casualty and specialty products to industrial, commercial and professional firms worldwide. For Portfolio Grader’s specific subcategory of Earnings Momentum, XL also gets an F. .
Top 10 Penny Companies To Own For 2015: Maximus Inc (MMS)
MAXIMUS, Inc., incorporated on October 18, 2007, provides business process services (BPS) to government health and human services agencies under its mission of Helping Government Serve the People. The Company is primarily focused on operating government-sponsored programs, such as Medicaid, Children's Health Insurance Program (CHIP), health insurance exchanges and other health care reform initiatives, Medicare, welfare-to-work, child support services and other government programs.
The Company is one of the pure-play health and human services administrative providers to governments in the United States, Australia, Canada, the United Kingdom and Saudi Arabia. The Company�� segments include Health Services and Human Services. Effective July 1, 2013, MAXIMUS, Inc. acquired Health Management Ltd.
Health Services Segment
The Company's Health Services segment provides a variety of business process services, as well as related consulting services, for state, provincial and federal government programs, including Medicaid, CHIP, SNAP (Supplemental Nutrition Assistance Program), Medicare, the Affordable Care Act and Health Insurance BC (British Columbia). In this segment, the Company's BPS and consulting services include government health insurance program administration; Health insurance program eligibility and enrollment services to improve access to health care for citizens and help beneficiaries make the best choice for their health insurance coverage; Eligibility and enrollment modernization for government health benefit programs; Health insurance exchange design and operations; Consumer outreach and education, including multilingual customer contact centers and multi-channel self-service options, such as Web-based portals, for easy enrollment; Application assistance and independent enrollment counseling to beneficiaries; Premium payment processing and administration, such as invoicing and reconciliation; Objective, evidence-based health appeals; Independent medical! reviews; Health plan oversight; eHealth solutions with the Medigent product suite; Medicaid Management Information System (MMIS) planning and oversight, and Specialized program consulting services.
Human Services Segment
The Company's Human Services segment provides federal, national, state and county human services agencies with a variety of business process services, as well as related consulting services for welfare-to-work, child support, higher education and K-12 special education programs. The Company's services include welfare-to-work services, including eligibility determination, case management, job-readiness preparation, job search and employer outreach, job retention and career advancement, and selected educational and training services, to help disadvantaged individuals transition from government assistance programs to sustainable employment and economic independence; Full and specialized child support case management services, customer contact center operations, and program and systems consulting services; Management tools and professional consulting services for higher education institutions; K-12 special education case management solutions; Program consulting services, including independent verification and validation, cost allocation plans, repeatable management services and other specialized consulting offerings, and Tax credit and employer services.
The Company competes with Serco, Atos Origin and Ingeus.
Advisors' Opinion:- [By Ben Levisohn]
Shares of Iron Mountain have fallen 2.3% to $25.72 today, while comparable have been mixed. Leidos Holdings (LDOS) has ticked up 0.6% to $46.28 and Amdocs (DOX) has risen 0.8% to $37.20. Maximus (MMS), on the other hand, has fallen 1.2% to $46.22 and Xerox (XRX) is off 0.3% to $10.62.
- [By Michael Flannelly]
Analysts at Jefferies initiated coverage on business process services provider Maximus Inc. (MMS) late on Thursday, giving the stock a bullish rating because it has several competitive advantages and should benefit from the Affordable Care Act (Obamacare).
The analysts rate MMS as “Buy” and see shares reaching $47. This price target suggests a 20% upside to the stock’s Thursday closing price of $39.14.
“MMS is a leading government outsourced contractor that produces consistently strong results,” Jefferies analyst David Styblo commented. “The company has several competitive advantages and is highly focused on health and human service projects. This positions MMS to enjoy multi-year growth from the ACA and other opportunities with limited risk. The company’s predictable business model, solid balance sheet, and EPS visibility into FY2014 also support a Buy and $47 PT.”
Maximus shares were inactive during pre-market trading on Friday. The stock is up 23.83% year-to-date.
- [By Caroline Bennett]
Government health services company Maximus (NYSE: MMS ) has declared a quarterly dividend to be paid on Nov. 29 to investors of record as of Nov. 15.
- [By Dan Caplinger]
Dow 16,000, S&P 1,800, and Nasdaq 4,000 didn't become reality today, but each of these benchmarks came close to reaching those respective levels as investors continued to respond favorably to the macroeconomic and monetary-policy environment going forward. But despite the market's broad gains, Electronic Arts (NASDAQ: EA ) , Maximus (NYSE: MMS ) , and Western Union (NYSE: WU ) gave up ground today with fairly substantial drops. Let's take a closer look at why these stocks bucked the market's favorable trend today.
Top 5 Sliver Companies To Watch In Right Now: Worthington Industries Inc.(WOR)
Worthington Industries, Inc. operates as a diversified metals processing company focusing on steel processing and manufactured metal products in the United States, Canada, and Europe. It processes flat-rolled steel and stainless steel for the automotive, construction, lawn and garden, hardware, furniture, office equipment, electrical control, tubing, leisure and recreation, appliance, agricultural, HVAC, container, and aerospace markets. The company also produces low-pressure liquefied petroleum gas and refrigerant gas cylinders; high-pressure and industrial/specialty gas cylinders; seamless steel high pressure cylinders for compressed natural gas storage in motor vehicles; aluminum-lined, composite-wrapped high-pressure cylinders; airbrake tanks; and consumer products. In addition, it produces recovery tanks for refrigerant gases; air reservoirs for truck and trailer original equipment manufacturers; and Balloon Time helium kits. Further, the company designs and manufactu res reusable custom platforms, racks, and pallets made of steel for supporting, protecting, and handling products throughout the shipping process; provides framing systems and stairs for mid-rise buildings, and current and past model automotive service stampings; designs, builds, and supplies light gauge steel framed commercial structures and multi-family housing units; supplies and constructs metal framing products for single family housing with a focus on military housing; and manufactures pre-engineered steel egress stair solutions. Worthington Industries was founded in 1955 and is headquartered in Columbus, Ohio.
Advisors' Opinion:- [By Ben Levisohn]
Shares of Harsco have gained 4.7% to $26.43 today at 1:16 p.m., outpacing other construction & engineering companies. Dycom (DY) has advanced 0.5% to $30, KBR Inc. (KBR) has ticked up 0.1% to $33.03, Worthington Industries�(WOR) has risen 2.8% to $38.85�and Tutor Perini (TPC) has rallied 3.6% to $22.46.
Top 5 Sliver Companies To Watch In Right Now: Vermilion Energy Inc (VET)
Vermilion Energy Inc. (Vermilion), is engaged in the business of oil and natural gas exploitation, development, acquisition and production in Australia, Canada, France, Ireland and the Netherlands. As of December 31, 2011, Vermilion holds an average working interest of 68.5% in 395,616 (271,067 net) acres of developed land, 582 (396 net) producing natural gas wells and 319 (198 net) producing oil wells in Canada. Vermilion holds an 83.6% working interest in 193,017 acres of developed land in the Aquitaine and Paris Basins. Vermilion's Netherlands assets consist of eight onshore concessions and one offshore concession located in the northern part of the country. In October 2013, Vermilion Energy Inc, through its wholly owned subsidiary acquired Northern Petroleum Nederland B.V. Advisors' Opinion:- [By Marc Bastow]
Oil exploration and production company Vermillion Energy (VET) raised its monthly dividend 7.5% to 21.50 cents (Canadian) per share, and is expected to be payable on February 17.
VTE Dividend Yield: 1.52%
Top 5 Sliver Companies To Watch In Right Now: Trovagene Inc (TROV)
TrovaGene, Inc. (TrovaGene), incorporated on April 26, 2002, is a development-stage molecular diagnostic company that focuses on the development and marketing of urine-based nucleic acid tests for patient/disease screening and monitoring. The Company's novel tests predominantly use transrenal DNA (Tr-DNA) and transrenal RNA (Tr-RNA). The Company's technology is used to all transrenal nucleic acids (Tr-NA). The Company�� urine-based test addresses market needs, such as women�� healthcare-fetal medicine-down syndrome, infectious diseases, cancer testing, transplantation, drug development and monitoring of therapeutic outcomes, ultra-sensitive analytical and detection system, technologies for the collection, shipment and storage of urine specimens, and transrenal nucleic acid extraction, and instrumentation/system platform.
On January 18, 2011, the Company entered into an asset purchase agreement pursuant to which the Company acquired a hybridoma able to produce a monoclonal antibody targeting the NPM1 biomarker. On February 8, 2011, the Company entered into a sublicense agreement with MLL Munchner Leukamielabor (MLL). In July, 2011, the Company entered into a sublicense agreement with Fairview Health Services (Fairview) for NPM1 patent rights.
In October 2011, the Company entered into a license agreement pursuant to which the Company licensed the patent rights to a specific gene mutation with respect to chronic lymphoblastic leukemia. On December 12, 2011, the Company entered into a license agreement pursuant to which the Company licensed the patent rights to hairy cell leukemia biomarkers. On February 1, 2012, the Company acquired the clinical laboratory improvement amendments (CLIA) laboratory assets of MultiGEN Diagnostics, Inc. (MultiGEN).
Advisors' Opinion:- [By Roberto Pedone]
TrovaGene (TROV) is a development stage molecular diagnostic company focused on the development and marketing of urine-based nucleic acid tests for patient/disease screening and monitoring. This stock closed up 6% to $10.02 in Friday's trading session.
Friday's Volume: 712,000
Three-Month Average Volume: 183,106
Volume % Change: 294%From a technical perspective, TROV ripped higher here into all-time high territory with heavy upside volume. This stock has been uptrending strong for the last month and change, with shares soaring higher from its low of $5.75 to its new all-time high of $10.20. During that move, shares of TROV have been making mostly higher lows and higher highs, which is bullish technical price action. That move has also been accompanied by bullish upside volume flows.
Traders should now look for long-biased trades in TROV as long as it's trending above its recent breakout level of $8.83, and then once it sustains a move or close above its all-time high of $10.20 with volume that hits near or above 183,106 shares. If we get that move soon, then TROV will set up to enter new all-time high territory, which is bullish technical price action. Some possible upside targets off that move are $13 to $15.
- [By Daniel Lauchheimer]
In the past few weeks, I wrote two articles about TrovaGene (TROV) -- one detailing the history of the DNA market generally and the molecular diagnostics -- and TROV's place therein -- market specifically, and the second detailing the company's internal valuation. In this article, I will value TROV on an external, relative basis. Specifically, I will compare TROV to another molecular diagnostics company, Exact Sciences (EXAS), and try to show that while the market seems to have given EXAS a fair shake, it has not done the same for TROV. I will prove this argument by looking at both companies' addressable markets, and their respective progress at bringing the products to market. However, before we take this deep dive into both companies, I will take a moment to review each of the companies' products, so we have a strong background before turning to the deeper analysis.
- [By David Goodboy]
Fortunately, diagnostic issues may soon be a thing of the past. Several publicly traded companies are currently making great strides in the field of medical diagnostics, and my favorite company right now in that arena is TrovaGene (Nasdaq: TROV).
No comments:
Post a Comment